Researchers assessed the long-term effectiveness of tumor necrosis factor inhibitors (TNFis) in patients with psoriatic arthritis who were exposed to at least 1 TNFi.
Positive topline data were announced from the phase 3 SELECT-PsA 1 study of upadacitinib, a Janus Kinase (JAK) inhibitor, in adult patients with active psoriatic arthritis who have had an inadequate response to at least 1 nonbiologic disease modifying antirheumatic drug (DMARD).
Researchers evaluated the psychometric properties of 3 patient-reported outcomes, HAQ-DI, PCS12, and PsAID-FC to assess physical function in patients with psoriatic arthritis.
Using high-resolution peripheral quantitative CT, the researchers compared the bone structure and microstructure in the metacarpal heads among patients with psoriatic arthritis and healthy controls.
Researchers examined gastrointestinal (GI) risk and patient-reported outcomes, including GI-related symptoms, adherence to nonsteroidal anti-inflammatory drugs, disease activity, and quality of life in ankylosing spondylitis.
Expression of interleukin (IL)-17A and IL-17F and the functional response to these cytokines were found to be comparable in spondyloarthritis and rheumatoid arthritis synovitis.
Patients with psoriasis showed an increased risk for ESRD development although patients who received systemic anti-psoriasis agents did not, a nationwide cohort study reveals.
In patients with axial spondyloarthritis, use of lateral DXA, as opposed to the conventional anteroposterior projection, significantly increased the prevalence of low BMD measurements.
